Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Xbiome Inc. currently manages a patent portfolio with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this matter is overseen by 1 distinct examiner. This limited number of examiners suggests a streamlined interaction with the patent office for the company's current filings. The case is being processed within 1 distinct art unit, which provides a consistent technical environment for the examination.
IANNUZO, NATALIE NMN is designated as the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Because the total count of 1 pending office action covers all active cases, this examiner is the sole official reviewing the company's applications. This concentration of work allows the applicant to focus their legal strategy on the specific requirements of the examiner. The presence of 1 distinct art unit further simplifies the administrative tracking of the portfolio's progress through the patent office and helps in preparing for potential interviews.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790378 | COMPOSITIONS COMPRISING BACTERIAL SPECIES AND METHODS RELATED THERETO | IANNUZO, NATALIE NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790378 | COMPOSITIONS COMPRISING BACTERIAL SPECIES AND METHODS RELATED THERETO | IANNUZO, NATALIE NMN | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17790378 | COMPOSITIONS COMPRISING BACTERIAL SPECIES AND METHODS RELATED THERETO | IANNUZO, NATALIE NMN | 1653 | §112 | Non-Final OA | — | Pending | Jul 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXbiome Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Natalie Nmn Iannuzo has the most, with 1 of Xbiome Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
